Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks

• Verfasst von: Speer, Claudius [VerfasserIn]
• Verfasst von: Schaier, Matthias [VerfasserIn]
• Verfasst von: Nußhag, Christian [VerfasserIn]
• Verfasst von: Töllner, Maximilian [VerfasserIn]
• Verfasst von: Buylaert, Mirabel [VerfasserIn]
• Verfasst von: Kälble, Florian [VerfasserIn]
• Verfasst von: Reichel, Paula [VerfasserIn]
• Verfasst von: Grenz, Julia [VerfasserIn]
• Verfasst von: Süsal, Caner [VerfasserIn]
• Verfasst von: Zeier, Martin [VerfasserIn]
• Verfasst von: Schnitzler, Paul [VerfasserIn]
• Verfasst von: Morath, Christian [VerfasserIn]
• Verfasst von: Klein, Katrin [VerfasserIn]
• Verfasst von: Benning, Louise [VerfasserIn]
• Titel: Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks
• Verf.angabe: Claudius Speer, Matthias Schaier, Christian Nusshag, Maximilian Töllner, Mirabel Buylaert, Florian Kälble, Paula Reichel, Julia Grenz, Caner Süsal, Martin Zeier, Paul Schnitzler, Christian Morath, Katrin Klein and Louise Benning
• E-Jahr: 2021
• Jahr: 4 October 2021
• Umfang: 12 S.
• Fussnoten: Gesehen am 26.11.2021
• Titel Quelle: Enthalten in: Vaccines
• Ort Quelle: Basel : MDPI, 2013
• Jahr Quelle: 2021
• Band/Heft Quelle: 9(2021), 10, Artikel-ID 1130, Seite 1-12
• ISSN Quelle: 2076-393X
• DOI: doi:10.3390/vaccines9101130
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: BNT162b2
• Sach-SW: COVID-19
• Sach-SW: COVID-19 vaccination
• Sach-SW: hemodialysis
• Sach-SW: humoral response
• Sach-SW: peritoneal dialysis
• Sach-SW: SARS-CoV-2
• Sach-SW: vaccination strategy
• K10plus-PPN: 177937576X

Abstract

It has been demonstrated that patients on hemo- or peritoneal dialysis are particularly susceptible to SARS-CoV-2 infection and impaired seroconversion compared to healthy controls. Follow-up data on vaccination response in dialysis patients is limited but is greatly needed to individualize and guide (booster) vaccination strategies. In this prospective, multicenter study we measured anti-spike S1 and neutralizing antibodies in 124 hemodialysis patients, 41 peritoneal dialysis patients, and 20 age- and sex-matched healthy controls over 12 weeks after homologous BNT162b2 vaccination. Compared to healthy controls, both hemodialysis and peritoneal dialysis patients had lower anti-S1 IgG antibodies (median (IQR) 7.0 (2.8-24.3) and 21.8 (5.8-103.9) versus 134.9 (23.8-283.6), respectively; p < 0.001 and p < 0.05) and a reduced SARS-CoV-2 spike protein-ACE2 binding inhibition caused by vaccine-induced antibodies (median (IQR) 56% (40-81) and 77% (52-89) versus 96% (90-98), respectively; p < 0.001 and p < 0.01) three weeks after the second vaccination. Twelve weeks after the second vaccination, the spike protein-ACE2 binding inhibition significantly decreased to a median (IQR) of 45% (31-60) in hemodialysis patients and 55% (36-78) in peritoneal dialysis patients, respectively (p < 0.001 and p < 0.05). Peritoneal dialysis patients mounted higher antibody levels compared with hemodialysis patients at all time points during the 12-week follow-up. Individual booster vaccinations in high-risk individuals without seroconversion or rapidly waning neutralizing antibody levels are required and further data on the neutralization of emerging variants of concern in these patients are urgently needed.